M&A / Deals Isomorphic Labs receives $2.1bn for AI drug development Pharmaceutical TechnologyIsomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale. Read full story Post navigation Previous: Makary resigns, with Diamantas named as acting FDA commissionerNext: Novo, Lilly trade oral GLP-1 data readouts at ECO Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026